FLT3 and myeloid leukemia: The present study, together with studies by Fernandes et al. [10] on this class of indolinone compounds, seem to suggest that future obtainment of a candidate for an innovative drug for the treatment of different cancer types, including myeloid leukemia, is possible, since some compounds, particularly IAF79, have been shown to exhibit possible promising dual activity against Aurora B/FLT3 and have promising molecular patterns that can be further investigated synthetically in the search for new anticancer drug candidates to build on studies that have already been carried out.